Is Globus Medical (GMED) Undervalued Or Is Its Recent Rebound Already Priced In?
Globus Medical (GMED) stock drew renewed attention after its recent trading move, with the price closing at $81.42. Investors are now reassessing how its business profile and valuation stack up.
See our latest analysis for Globus Medical.
That latest move sits within a mixed picture. The 7 day share price return of 7.84% contrasts with a 30 day share price decline of 3% and a 90 day share price decline of 9.71%, while the 1 year total shareholder return of 52.33% points to stronger long run momentum.
If you are weighing Globus Medical alongside other opportunities in healthcare technology, this is a good moment to broaden your research and scan 41 healthcare AI stocks.
After a 7 day rebound but weaker recent months, Globus Medical at US$81.42 leaves investors split between seeing fresh upside ahead and believing most of the rerating is already in the rearview. How does the current valuation line up?
Most Popular Narrative: 24.2% Undervalued
Relative to the last close at $81.42, the most followed narrative pegs Globus Medical's fair value at about $107.42, which implies meaningful upside in that framework.
Continued innovation and adoption of robotics, navigation, and minimally invasive procedures including expansion of the ExcelsiusGPS ecosystem, launch of the Excelsius XR headset, and a robust product pipeline position Globus to participate in healthcare digitization trends, with the potential for higher ASPs, stronger market differentiation, and improved gross margins over time.
Want to see what this robotics heavy story assumes under the hood? Revenue, margins and the future profit multiple are all tightly specified. The full narrative shows exactly how those moving parts add up to that fair value number.
Result: Fair Value of $107.42 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the Globus Medical story also carries execution risks, including slower international traction and integration hurdles from NuVasive and Nevro that could pressure margins and growth assumptions.
Find out about the key risks to this Globus Medical narrative.
Next Steps
The mix of optimism and caution around Globus Medical is clear, so this is a good time to move fast and test the data yourself. To see which potential upsides others are focusing on, review the 5 key rewards.
Looking for more investment ideas beyond Globus Medical?
If Globus Medical has sharpened your focus on quality opportunities, do not stop here. Use the Simply Wall Street Screener to uncover other stocks that fit your approach.
- Target resilient compounding potential by scanning companies with proven earnings support and sensible valuations through the 49 high quality undervalued stocks.
- Prioritize capital protection by focusing on businesses that score well on stability and financial risk using the 85 resilient stocks with low risk scores.
- Spot earlier stage standouts with solid fundamentals before they become widely followed by running the screener containing 21 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com